子宮がん治療薬・診断薬市場- 世界の産業規模、動向、機会、予測、がんの種類別、治療法別、診断方法別、地域別、競合別、2020～2030年

世界の子宮がん治療薬・診断薬市場は、2024年に231億米ドルと評価され、2030年までのCAGRは5.75%で、予測期間中に目覚ましい成長を遂げると予測されています。

子宮体がんは子宮内膜がんとも呼ばれ、子宮内膜に発生するがんの一種です。子宮は女性の生殖器官であり、妊娠中に受精卵が着床し、開発中の胎児が成長する場所です。子宮体がんは、子宮内膜内で異常な細胞が制御不能に増殖することで発生します。子宮体がんは多くの場合、異常な膣出血、骨盤痛、排尿または排便習慣の変化などの症状を呈します。子宮体がんの危険因子としては、肥満、ホルモンバランスの乱れ、家族歴、リンチ症候群のような特定の遺伝的疾患が挙げられます。子宮体がんの診断には通常、病歴評価、身体診察、画像検査（経腟超音波検査、MRI検査、CT検査など）、組織生検（通常は子宮内膜生検または拡張掻爬術によって得られる）を組み合わせる。がんの病期分類は、がんの広がりの程度を判定し、治療方針の決定に役立ちます。子宮体がんの治療は、病期、病型、個々の患者の要因によって異なるが、手術（子宮摘出術など）、放射線療法、化学療法、標的療法、場合によっては免疫療法などが行われることが多いです。早期発見と時宜を得た治療は、多くの子宮体がん患者にとって良好な転帰をもたらします。MRIやCTスキャンなどの画像診断や分子検査、遺伝子検査などの診断技術の向上により、子宮体がんはより早く、より正確に診断できるようになりました。継続的な研究開発の努力は、子宮体がん治療薬の革新につながりました。これには標的療法、免疫療法、新規化学療法剤の開発が含まれます。特に先進国では高齢化が進み、子宮体がんの有病率が高くなっています。高齢者はこの種のがんのリスクが高いです。

市場促進要因

高齢者人口の増加

主な市場課題

併存疾患と集学的ケア

主要市場動向

精密医療

地域別インサイト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の子宮がん治療薬・診断薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • がんの種類別（子宮内膜腺がん、腺扁平上皮がん、乳頭漿液性がん、子宮肉腫）
  • 治療法別（手術、免疫療法、放射線療法、化学療法、その他）
  • 診断方法別（生検、骨盤超音波、子宮鏡検査、子宮拡張掻爬、CTスキャン）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の子宮がん治療薬・診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の子宮がん治療薬・診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の子宮がん治療薬・診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の子宮がん治療薬・診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの子宮がん治療薬・診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の子宮がん治療薬・診断薬市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Ariad Pharmaceuticals, Inc.
• Abbott Laboratories Inc.
• Becton, Dickinson & Co.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Siemens Healthineers AG.
• F. Hoffmann-La Roche AG

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Uterine Cancer Therapeutics & Diagnostics Market was valued at USD 23.10 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.75% through 2030. Uterine cancer, also known as endometrial cancer, is a type of cancer that originates in the lining of the uterus, called the endometrium. The uterus is a female reproductive organ where a fertilized egg implants and a developing fetus grows during pregnancy. Uterine cancer occurs when there is uncontrolled growth of abnormal cells within the endometrial lining. Uterine cancer often presents with symptoms such as abnormal vaginal bleeding, pelvic pain, and changes in urinary or bowel habits. The risk factors for uterine cancer include obesity, hormone imbalances, a family history of the disease, and certain genetic conditions like Lynch syndrome. Diagnosis of uterine cancer typically involves a combination of medical history evaluation, physical examination, imaging studies (such as transvaginal ultrasound, MRI, or CT scans), and tissue biopsy (usually obtained through endometrial biopsy or dilation and curettage). Staging of the cancer helps determine the extent of its spread and guides treatment decisions. Treatment for uterine cancer varies depending on the stage, type, and individual patient factors but often includes surgery (such as hysterectomy), radiation therapy, chemotherapy, targeted therapy, and, in some cases, immunotherapy. Early detection and timely treatment can lead to favorable outcomes for many uterine cancer patients. Improved diagnostic techniques, including imaging modalities like MRI and CT scans, as well as molecular and genetic testing, enabled earlier and more accurate diagnosis of uterine cancer. Ongoing research and development efforts led to innovations in uterine cancer therapeutics. This included the development of targeted therapies, immunotherapies, and novel chemotherapeutic agents. The aging population, particularly in developed nations, contributed to a higher prevalence of uterine cancer. Older individuals are at higher risk for this type of cancer.

Key Market Drivers

Rising Geriatric Population

The rising geriatric population is a key driver fueling the growth of the global uterine cancer therapeutics & diagnostics market. The global population aged 65 and older is expected to more than double, increasing from 761 million in 2021 to 1.6 billion by 2050. The 80+ demographic is expanding at an even faster rate. This irreversible demographic shift is set to reshape industries, drive demand for age-specific healthcare solutions, and create new market opportunities across pharmaceuticals, medical diagnostics, elderly care services, and insurance sectors. As the global population ages, the prevalence of uterine cancer-particularly endometrial cancer-has increased, leading to a higher demand for advanced diagnostics, innovative treatments, and specialized healthcare services. Below is a detailed analysis of how the aging demographic is shaping this market. Uterine cancer is more common among postmenopausal women, with the majority of cases diagnosed in women aged 50 and above. Endometrial cancer (EC) ranks as the sixth most prevalent cancer among women globally, with its incidence surging significantly over the past two decades. In 2019 alone, 435,041 new cases were diagnosed, resulting in 91,641 fatalities worldwide. This sharp rise underscores the growing burden on healthcare systems, accelerating demand for advanced diagnostics, targeted therapies, and innovative treatment solutions in the oncology market. As global life expectancy increases, the number of elderly women at risk also grows, leading to a direct rise in demand for cancer diagnostics and therapeutics. With an aging population, healthcare providers are prioritizing early detection and preventive screening programs to manage uterine cancer effectively. Governments and healthcare organizations are actively investing in: Routine gynecological screenings for older women, Biomarker-based diagnostic tests to detect cancer in early stages, AI-driven imaging solutions (MRI, PET scans) for precise detection. This increasing emphasis on early diagnosis and regular screenings is driving the market for diagnostic devices, pathology services, and molecular testing kits.

Key Market Challenges

Comorbidities and Multidisciplinary Care

Many uterine cancer patients have comorbid conditions, such as diabetes, hypertension, heart disease, or obesity. Managing uterine cancer alongside these comorbidities can complicate treatment decisions. Healthcare providers must weigh the benefits of aggressive cancer treatment against the potential risks and interactions with existing health conditions and medications. Comorbidities can affect a patient's ability to tolerate cancer treatments, such as surgery, chemotherapy, or radiation therapy. For example, individuals with heart disease may be at increased risk during surgery or may not tolerate certain chemotherapy regimens. Patients with multiple health conditions often take multiple medications. The potential for drug interactions between cancer therapies and medications for comorbidities must be carefully managed to avoid adverse effects. Due to the complexity of managing uterine cancer in patients with comorbidities, a multidisciplinary approach involving oncologists, surgeons, cardiologists, endocrinologists, and other specialists is often necessary. Coordinating care and communication among these specialists can be challenging. Each patient's case is unique, requiring individualized treatment plans that consider both the cancer and comorbidities. This necessitates close collaboration among healthcare providers. Determining the optimal sequencing of cancer treatments and interventions for comorbidities is crucial. For example, deciding whether to address heart disease or uterine cancer first can impact treatment outcomes.

Key Market Trends

Precision Medicine

Advances in genetic testing allowed for the comprehensive profiling of uterine cancer tumors. This profiling identified specific genetic mutations and alterations that drive cancer growth. Oncologists could use this information to select targeted therapies that were more likely to be effective for individual patients. Researchers were identifying and validating specific biomarkers associated with uterine cancer. These biomarkers could be used for early detection, prognosis assessment, and treatment decision-making. Precision medicine guided treatment decisions based on the molecular characteristics of a patient's tumor. This approach minimized the use of one-size-fits-all treatments and aimed to improve treatment efficacy while reducing side effects. Immunotherapy drugs, which stimulate the patient's immune system to target cancer cells, were being explored as part of precision medicine approaches for uterine cancer. Some patients with specific molecular profiles responded well to immunotherapy. Precision medicine was driving the design of clinical trials that focused on specific genetic subtypes of uterine cancer. These trials aimed to test new therapies and treatment combinations tailored to the molecular profiles of patients. Precision medicine also played a role in assessing a patient's risk of developing uterine cancer based on their genetic and environmental factors. This could inform prevention and early detection strategies.

Regional Insights

The North America region was the largest market in the Global Uterine Cancer Therapeutics & Diagnostics Market in 2024. North America, particularly the United States, has one of the highest healthcare spending rates in the world. This substantial investment in healthcare infrastructure and research and development contributes to advancements in uterine cancer therapeutics and diagnostics. The region boasts advanced healthcare facilities, medical technology, and a well-developed healthcare system. This allows for early detection, accurate diagnosis, and state-of-the-art treatment options for uterine cancer patients. North America is home to numerous pharmaceutical and biotechnology companies that invest heavily in cancer research, including uterine cancer. These companies develop innovative therapeutics and diagnostic tools for the market. The United States hosts a large number of clinical trials for various cancer types, including uterine cancer. Clinical trials are critical for testing new treatments and diagnostic methods, attracting patients from around the world.

Key Market Players

• Ariad Pharmaceuticals, Inc.
• Abbott Laboratories Inc.
• Becton, Dickinson & Co.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Siemens Healthineers AG.
• F. Hoffmann-La Roche AG

Report Scope:

In this report, the Global Uterine Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uterine Cancer Therapeutics & Diagnostics Market, By Cancer Type:

• Endometrial Adenocarcinoma
• Adenosquamous Carcinoma
• Papillary Serous Carcinoma
• Uterine Sarcoma

Uterine Cancer Therapeutics & Diagnostics Market, By Therapeutics:

• Surgery
• Immunotherapy
• Radiation Therapy
• Chemotherapy
• Others

Uterine Cancer Therapeutics & Diagnostics Market, By Diagnostics:

• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• Dilation and Curettage
• CT scan

Uterine Cancer Therapeutics & Diagnostics Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uterine Cancer Therapeutics & Diagnostics Market.

Available Customizations:

Global Uterine Cancer Therapeutics & Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma)
  • 5.2.2. By Therapeutics (Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, Others)
  • 5.2.3. By Diagnostics (Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, CT scan)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Therapeutics
  • 6.2.3. By Diagnostics
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Therapeutics
      • 6.3.1.2.3. By Diagnostics
  • 6.3.2. India Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Therapeutics
      • 6.3.2.2.3. By Diagnostics
  • 6.3.3. Australia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Therapeutics
      • 6.3.3.2.3. By Diagnostics
  • 6.3.4. Japan Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Cancer Type
      • 6.3.4.2.2. By Therapeutics
      • 6.3.4.2.3. By Diagnostics
  • 6.3.5. South Korea Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Cancer Type
      • 6.3.5.2.2. By Therapeutics
      • 6.3.5.2.3. By Diagnostics

7. Europe Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Therapeutics
  • 7.2.3. By Diagnostics
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Therapeutics
      • 7.3.1.2.3. By Diagnostics
  • 7.3.2. Germany Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Therapeutics
      • 7.3.2.2.3. By Diagnostics
  • 7.3.3. Spain Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Therapeutics
      • 7.3.3.2.3. By Diagnostics
  • 7.3.4. Italy Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Therapeutics
      • 7.3.4.2.3. By Diagnostics
  • 7.3.5. United Kingdom Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Therapeutics
      • 7.3.5.2.3. By Diagnostics

8. North America Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Therapeutics
  • 8.2.3. By Diagnostics
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Therapeutics
      • 8.3.1.2.3. By Diagnostics
  • 8.3.2. Mexico Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Therapeutics
      • 8.3.2.2.3. By Diagnostics
  • 8.3.3. Canada Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Therapeutics
      • 8.3.3.2.3. By Diagnostics

9. South America Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Therapeutics
  • 9.2.3. By Diagnostics
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Therapeutics
      • 9.3.1.2.3. By Diagnostics
  • 9.3.2. Argentina Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Therapeutics
      • 9.3.2.2.3. By Diagnostics
  • 9.3.3. Colombia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Therapeutics
      • 9.3.3.2.3. By Diagnostics

10. Middle East and Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Therapeutics
  • 10.2.3. By Diagnostics
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Therapeutics
      • 10.3.1.2.3. By Diagnostics
  • 10.3.2. Saudi Arabia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Therapeutics
      • 10.3.2.2.3. By Diagnostics
  • 10.3.3. UAE Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Therapeutics
      • 10.3.3.2.3. By Diagnostics

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Uterine Cancer Therapeutics & Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Ariad Pharmaceuticals, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Product & Service Offerings
  • 16.1.3. Recent Developments
  • 16.1.4. Financials (If Listed)
  • 16.1.5. Key Personnel
  • 16.1.6. SWOT Analysis
• 16.2. Abbott Laboratories Inc.
• 16.3. Becton, Dickinson & Co.
• 16.4. GlaxoSmithKline Plc
• 16.5. Merck & Co., Inc.
• 16.6. Novartis AG
• 16.7. Sanofi SA
• 16.8. Siemens Healthineers AG.
• 16.9. F. Hoffmann-La Roche AG

17. Strategic Recommendations

18. About Us & Disclaimer